24 November 2026

ASX Announcement

Results of Annual General Meeting

MELBOURNE, Australia, 24 November 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA**; **Island** or **the Company**) advises that its Annual General meeting was held today at 1:00pm (AEDT).

The Company advises that all resolutions were carried.

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and proxies received in respect of each resolution are set out in the attached proxy summary.

– Ends –

The release of this announcement was authorised by CEO and Managing Director, David Foster.

For further information, please contact:

David Foster
Managing Director
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Results of Meeting

Island Pharmaceuticals Limited

Annual General Meeting

Tuesday, 24 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	29,928,777 29.52%	9,894,216 9.76%	26,863	61,577,412 60.73%	92,978,581 90.38%	9,894,216 9.62%	26,863	-
2 Re-election of Christopher Ntoumenopoulos as Director	P	104,784,712 74.83%	14,114,399 10.08%	2,655,478	21,137,339 15.09%	127,394,443 90.03%	14,114,399 9.97%	2,655,478	Carried
3 Approval of increased placement capacity	P	68,687,215 48.14%	12,438,375 8.72%	19,975	61,546,365 43.14%	131,705,972 91.37%	12,438,375 8.63%	19,975	Carried
4 Ratification of prior issue of Broker Options	P	73,601,134 51.63%	7,382,844 5.18%	130,538	61,577,415 43.19%	136,650,941 94.87%	7,382,844 5.13%	130,538	Carried
5 Adoption of new Employee Incentive Plan	P	35,363,276 34.96%	4,232,542 4.18%	285,087	61,546,367 60.85%	98,382,035 95.88%	4,232,542 4.12%	285,087	Carried
6 Approval of grant of securities to Mr Christopher Ntoumenopoulos	P	64,528,305 63.78%	15,536,133 15.35%	246,540	21,116,295 20.87%	87,116,992 84.87%	15,536,133 15.13%	246,540	Carried
7 Approval of grant of securities to Dr David Foster	P	35,145,486 34.70%	4,589,442 4.53%	1,457,493	61,556,369 60.77%	98,174,247 95.53%	4,589,442 4.47%	1,457,493	Carried
8 Approval of grant of securities to Mr Jason Carroll	P	28,184,477 27.83%	11,550,451 11.40%	135,977	61,556,370 60.77%	91,213,239 88.76%	11,550,451 11.24%	135,977	Carried
9 Section 195 approval	P	27,244,776 26.92%	12,291,534 12.15%	233,546	61,657,420 60.93%	90,374,588 88.03%	12,291,534 11.97%	233,546	Carried